There are currently 68 active clinical trials seeking participants for Coronary Artery Disease research studies. The states with the highest number of trials for Coronary Artery Disease participants are Florida, California, New York and Texas.
Polypill in Acute Coronary Syndrome
NCT05514938
Recruiting
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low. This contributes to worse patient outcomes and increased risk of morbidity and mortality. The once-daily polypill leverages a population-based strategy that has previously demonstrated efficacy in improving adherence and access to therapy in low-resource settings, making it an innovative approach for improving post-ACS ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Register for Updates
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
NCT05908331
Recruiting
A Prospective, Multicenter, Randomized, Two-Arm, Single-blind Superiority Trial to Evaluate the Safety and Efficacy of the MagicTouch™ Sirolimus- Coated Balloon in the Treatment of Coronary Drug-Eluting Stent In-Stent Restenosis. Subjects with prior DES implantation presenting with ISR lesions undergoing PCI will be randomized into two groups: treatment with the MagicTouch™ sirolimus-coated balloon or POBA on a 2:1 basis. Approximately 492 subjects will be enrolled in the randomized study in a... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/13/2025
Locations: Cardiology, PC - Princeton Baptist Medical Center, Birmingham, Alabama +27 locations
Conditions: In-Stent Restenosis, Cardiovascular Diseases, Coronary Artery Disease
Register for Updates
Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
NCT06814587
Recruiting
The goal of this clinical trial is to evaluate a novel imaging approach that combines hyperpolarized 13C pyruvate magnetic resonance imaging (HP-13C-MRI) and \[¹⁸F\]Fluorodeoxyglucose positron emission tomography (FDG-PET) in a single exam to improve the prognostic assessment of ischemic cardiomyopathy. The main questions this study aims to answer are: Primary Hypothesis: Can the simultaneous acquisition of HP-13C-MRI and FDG-PET data improve the metabolic, viability, and mechanical function as... Read More
Gender:
ALL
Ages:
Between 20 years and 80 years
Trial Updated:
02/05/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Register for Updates
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
NCT05611307
Recruiting
Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
02/05/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Testicular Cancer, Survivorship, ASCVD, Coronary Artery Disease, Lipid Disorder, Hypogonadism, Male, Cisplatin Adverse Reaction, Bone Marrow Transplant Complications
Register for Updates
CTSN Embolic Protection Trial
NCT06027788
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
02/05/2025
Locations: CHI St. Vincent Heart Institute, North Little Rock, Arkansas +27 locations
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Register for Updates
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter to Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
NCT05134012
Recruiting
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Iowa, Iowa City, Iowa +10 locations
Conditions: Coronary Artery Disease
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: HCA Los Robles, Thousand Oaks, California +26 locations
Conditions: Coronary Artery Disease
Register for Updates
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
NCT05681702
Recruiting
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e., switching from prasugrel or ticagrelor to clopidogrel while maintaining aspirin) and b) potent P2Y12 inhibitor monotherapy (i.e., maintaining prasugrel or ticagrelor and dropping aspirin). These strategies have been tested in a number of trials and have led to changes in practi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: University of Florida, Jacksonville, Florida
Conditions: Coronary Artery Disease
Register for Updates
A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction
NCT05332262
Recruiting
Despite the relative safety of PCI with new generation stents, peri-PCI thrombotic complications, including myocardial infarction and myocardial injury, are common in elective PCI, occurring in up to 30% of patients. Importantly, these events are associated with poor prognosis. The risk of peri-PCI myocardial infarction/myocardial injury has been in part attributed to HPR. The aim of this study is to prospectively validate the accuracy of the ABCD-GENE score in identifying stable CAD patients un... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Florida Jacksonville, Jacksonville, Florida
Conditions: Coronary Artery Disease
Register for Updates
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
NCT06691191
Recruiting
Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/22/2025
Locations: University of Florida Jacksonville, Jacksonville, Florida
Conditions: Coronary Artery Disease
Register for Updates
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
NCT06713239
Recruiting
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary atherosclerotic plaque assessment by AI-enabled quantitative software improves: certainty for diagnosis of CAD, control of CAD risk factors and efficiency of ICA referral with appropriate PCI compared to the usual care strategy based on current AHA/ACC guidelines for care of symptom... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Cardiology Associates of Mobile, Mobile, Alabama
Conditions: Coronary Artery Disease
Register for Updates
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
NCT04763200
Recruiting
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health after a heart procedure compared to the current standard of care.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/21/2025
Locations: University of Alabama, Birmingham, Alabama +133 locations
Conditions: Left Ventricular Dysfunction, Coronary Artery Disease
Register for Updates